Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10804781 | 0.98 | MAPT (0.41) | MAPTMMP1MMP2MMP3MMP9 | |
| SCHEMBL17162925 | 0.86 | MAPT (0.41) | MAPTFAAH | |
| SCHEMBL10780702 | 0.86 | MAPT (0.41) | MAPTFAAH | |
| SCHEMBL27519466 | 0.83 | RNPEP (0.40) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL27556849 | 0.83 | MAPT (0.38) | MAPTFAAHSMN1; SMN2 | |
| SCHEMBL1562153 | 0.82 | MAPT (0.39) | MAPT | |
| SCHEMBL6903324 | 0.82 | MMP1 (0.33) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL10783901 | 0.81 | MAPT (0.38) | MAPT | |
| SCHEMBL6909412 | 0.79 | MMP1 (0.35) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL334795 | 0.78 | MAPT (0.44) | MAPTMMP1MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104755510-A | Ziegler-Natta catalyst systems comprising a 1,2-phenylenedioate as internal donor and process for preparing the same | INDIAN OIL CORP LTD | 2015-07-01 | — | — | CN | claimed |
| CN-114599687-A | Ziegler-natta catalyst for olefin polymerization | 北欧化工公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-104755510-B | Ziegler natta catalyst system of internal donor and preparation method thereof is used as comprising 1,2 phenylene diester | 印度石油有限公司 | 2017-11-07 | — | — | CN | disclosed |
| CN-104755510-A | Ziegler-Natta catalyst systems comprising a 1,2-phenylenedioate as internal donor and process for preparing the same | INDIAN OIL CORP LTD | 2015-07-01 | — | — | CN | disclosed |
| US-8222404-B2 | [1,2,4]Thiadiazin-3-yl acetic acid compound and methods of making the acetic acid compound | ANADYS PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20120116077-A1 | [1,2,4]THIADIAZIN-3-YL ACETIC ACID COMPOUND[[S]] AND METHODS OF MAKING THE ACETIC ACID COMPOUND | ANADYS PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8097613-B2 | [1,2,4]thiadiazine 1,1-dioxide compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| WO-2009152166-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090306057-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| CN-1146585-C | catalyst component and catalyst for olefin polymerization | ض� | 2004-04-21 | — | — | CN | disclosed |
| US-6372800-B1 | IMMUNOSUPPRESSIVE EFFECT AND IS USEFUL AS AN INHIBITOR FOR THE REJECTION REACTION OCCURRING IN ORGAN OR BONE MARROW TRANSPLANTATION, AND AS A PREVENTIVE OR REMEDY FOR ARTICULAR RHEUMATISM, ATOPIC ECZEMA (DERMATITIS), BEHCET'S DISEASE, | MITSUBISHI PHARMA CORPORATION (JP) | 2002-04-16 | — | — | US | disclosed |
| EP-0778263-B1 | BENZENE COMPOUND AND MEDICINAL USE THEREOF | WELFIDE CORP (JP) | 2002-01-09 | — | — | EP | disclosed |
| CN-1292800-A | catalyst component and catalyst for olefin polymerization | MONTELL TECHNOLOGY COMPANY BV (NL) | 2001-04-25 | — | — | CN | disclosed |
| US-6187821-B1 | SUCH AS 2-AMINO-2-(3-(4-HEPTYLPHENYL)PROPYL)BUTANE-1,4-DIOL; IMMUNOSUPPRESSANT; ADMINISTERING TO TREAT OR PREVENT AUTOIMMUNE DISEASES AND ALLERGIES | WELFIDE CORPORATION (JP) | 2001-02-13 | — | — | US | disclosed |
| US-5948820-A | IMMUNOSUPPRESSANT; PREVENT REJECTION OF ORGAN TRANSPLANT;AUTOIMMUNE DISEASES; MULTIPLE SCLEROSIS; LUPUS; ANTIALLERGENS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0778263-A1 | BENZENE COMPOUND AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-06-11 | — | — | EP | disclosed |
| US-5010189-A | Processes for the preparation of 5-amino-4-hydroxy-valeric acid derivatives | CIBA-GEIGY CORPORATION (US) | 1991-04-23 | — | — | US | disclosed |
| US-4898977-A | Processes for the preparation of 5-amino-4-hydroxyvaleric acid derivatives | CIBA-GEIGY CORPORATION (US) | 1990-02-06 | — | — | US | disclosed |
| US-3997593-A | PREPARATION OF HYDROXY DIESTERS BY OXIDATION OF A DIESTER WITH NITRIC ACID | SANDOZ LTD. (CH) | 1976-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116077-A1 | [1,2,4]THIADIAZIN-3-YL ACETIC ACID COMPOUND[[S]] AND METHODS OF MAKING THE ACETIC ACID COMPOUND | ACMSD, ACACA, ALDH1A1 | MAPT 2195/4885MMP1 3929/4885MMP2 4225/4885 |
| US-20090306057-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | CYP2E1, CYP1A1, CYP1B1 | MAPT 2519/4885MMP1 3898/4885MMP2 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.